145 related articles for article (PubMed ID: 34174844)
1. Clinicopathologic features of TDO2 overexpression in renal cell carcinoma.
Pham QT; Taniyama D; Sekino Y; Akabane S; Babasaki T; Kobayashi G; Sakamoto N; Sentani K; Oue N; Yasui W
BMC Cancer; 2021 Jun; 21(1):737. PubMed ID: 34174844
[TBL] [Abstract][Full Text] [Related]
2. TDO2 Overexpression Is Associated with Cancer Stem Cells and Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Pham QT; Oue N; Sekino Y; Yamamoto Y; Shigematsu Y; Sakamoto N; Sentani K; Uraoka N; Yasui W
Oncology; 2018; 95(5):297-308. PubMed ID: 30134247
[TBL] [Abstract][Full Text] [Related]
3. TDO2 overexpression correlates with poor prognosis, cancer stemness, and resistance to cetuximab in bladder cancer.
Pham QT; Taniyama D; Akabane S; Harada K; Babasaki T; Sekino Y; Hayashi T; Sakamoto N; Sentani K; Oue N; Yasui W
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1417. PubMed ID: 34101386
[TBL] [Abstract][Full Text] [Related]
4. Essential Roles of TDO2 in Gastric Cancer: TDO2 Is Associated with Cancer Progression, Patient Survival, PD-L1 Expression, and Cancer Stem Cells.
Pham QT; Taniyama D; Akabane S; Takashima T; Maruyama R; Sekino Y; Sentani K; Yasui W; Oue N
Pathobiology; 2023; 90(1):44-55. PubMed ID: 35679834
[TBL] [Abstract][Full Text] [Related]
5. BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.
Sekino Y; Han X; Kobayashi G; Babasaki T; Miyamoto S; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Teishima J; Sakamoto N; Sentani K; Oue N; Yasui W; Matsubara A
Oncology; 2021; 99(4):240-250. PubMed ID: 33588420
[TBL] [Abstract][Full Text] [Related]
6. Circular RNA circZNF566 promotes hepatocellular carcinoma progression by sponging miR-4738-3p and regulating TDO2 expression.
Li S; Weng J; Song F; Li L; Xiao C; Yang W; Xu J
Cell Death Dis; 2020 Jun; 11(6):452. PubMed ID: 32532962
[TBL] [Abstract][Full Text] [Related]
7. TDO2 knockdown inhibits colorectal cancer progression via TDO2-KYNU-AhR pathway.
Zhao L; Wang B; Yang C; Lin Y; Zhang Z; Wang S; Ye Y; Shen Z
Gene; 2021 Aug; 792():145736. PubMed ID: 34051337
[TBL] [Abstract][Full Text] [Related]
8. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
[TBL] [Abstract][Full Text] [Related]
9. Tryptophan 2, 3‑dioxygenase promotes proliferation, migration and invasion of ovarian cancer cells.
Zhao Y; Tao F; Jiang J; Chen L; Du J; Cheng X; He Q; Zhong S; Chen W; Wu X; Ou R; Xu Y; Tang KF
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846800
[TBL] [Abstract][Full Text] [Related]
10. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of flotillin-2 is associated with renal cell carcinoma progression.
Yan Y; Yang FQ; Zhang HM; Che J; Zheng JH
Tumour Biol; 2014 Oct; 35(10):10479-86. PubMed ID: 25053596
[TBL] [Abstract][Full Text] [Related]
12. Pancancer Analysis of Revealed
Cui J; Tian Y; Liu T; Lin X; Li L; Li Z; Shen L
Dis Markers; 2022; 2022():5447017. PubMed ID: 36118672
[TBL] [Abstract][Full Text] [Related]
13. TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27.
Yu C; Rao D; Zhu H; Liu Q; Huang W; Zhang L; Liang H; Song J; Ding Z
Biomed Res Int; 2021; 2021():4708439. PubMed ID: 34423034
[TBL] [Abstract][Full Text] [Related]
14. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
15. Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ.
Kudo T; Prentzell MT; Mohapatra SR; Sahm F; Zhao Z; Grummt I; Wick W; Opitz CA; Platten M; Green EW
Front Immunol; 2020; 11():657. PubMed ID: 32477324
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.
Jiang J; Han P; Qian J; Zhang S; Wang S; Cao Q; Shao P
Exp Cell Res; 2020 Jul; 392(2):112029. PubMed ID: 32330508
[TBL] [Abstract][Full Text] [Related]
17. Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma.
Kobayashi G; Sentani K; Babasaki T; Sekino Y; Shigematsu Y; Hayashi T; Oue N; Teishima J; Matsubara A; Sasaki N; Yasui W
Cancer Sci; 2020 Mar; 111(3):1020-1027. PubMed ID: 31912588
[TBL] [Abstract][Full Text] [Related]
18. TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell Carcinoma.
Sekino Y; Han X; Babasaki T; Miyamoto S; Kitano H; Kobayashi G; Goto K; Inoue S; Hayashi T; Teishima J; Sakamoto N; Sentani K; Oue N; Yasui W; Matsubara A
Oncology; 2020; 98(10):689-698. PubMed ID: 32585672
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3 promotes CXCR2 to augment the stem-like property of renal cell carcinoma.
Huang CS; Tang SJ; Lee MH; Chang Wang CC; Sun GH; Sun KH
J Cell Mol Med; 2018 Dec; 22(12):5909-5918. PubMed ID: 30246456
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
